Loading
A phase 3 trial of Olaparib in ovarian cancer, run by AstraZeneca, active and no longer recruiting.
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy is a phase 3 interventional study registered as NCT01874353 by AstraZeneca, with 327 participants enrolled, started 2013-09-03 and due to reach its primary completion in 2016-09-19. Interventions recorded: Olaparib 300mg tablets and Placebo to match olaparib 300mg. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
327 enrolled.
95% CI 16.3 to 25.7; Figures from the ClinicalTrials.gov results section (first posted 2018-02-07), not from a publication · 95% CI 5.2 to 5.8 · 95% CI 6.5 to 16.6 · 95% CI 2.7 to NA
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1)primary | Olaparib 300mg Tablets (Global Cohort) | 196 | 19.1 months | - | - | link |
| Placebo Tablets (Global Cohort) | 99 | 5.5 months | ||||
| Olaparib 300mg Tablets (China Cohort) | 22 | 13.8 months | ||||
| Placebo Tablets (China Cohort) | 10 | 5.5 months |
Shares PARP inhibitors, Olaparib, Merck & Co. (MSD), AstraZeneca and the tag pipeline.
Shares PARP inhibitors, Olaparib, AstraZeneca and the tag pipeline.
Shares PARP inhibitors, Olaparib, AstraZeneca and the tag pipeline.
Shares Platinum-sensitive ovarian cancer, Ovarian cancer and the tag pipeline.
Shares PARP inhibitors, Olaparib, AstraZeneca, Ovarian cancer and the tag pipeline.
Shares PARP inhibitors, Olaparib, Merck & Co. (MSD) and the tag pipeline.
Shares PARP inhibitors, Olaparib and the tag pipeline.
Shares Platinum-sensitive ovarian cancer, Ovarian cancer and the tag pipeline.